Cargando…

Prognostic Markers in Head and Neck Cancer Patients Treated with Nivolumab

To investigate whether peripheral blood biomarkers predict the outcome of anti-PD-1 antibody treatment for head and neck squamous cell carcinoma (HNSCC). Patients treated with nivolumab for platinum-refractory recurrent or metastatic HNSCC were retrospectively reviewed. Fifty-three patients treated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishikawa, Daisuke, Suzuki, Hidenori, Koide, Yusuke, Beppu, Shintaro, Kadowaki, Shigenori, Sone, Michihiko, Hanai, Nobuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316608/ https://www.ncbi.nlm.nih.gov/pubmed/30477171 http://dx.doi.org/10.3390/cancers10120466

Ejemplares similares

Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab
por: Nishikawa, Daisuke, et al.
Publicado: (2020)

Lymph Node Ratio in Head and Neck Cancer with Submental Flap Reconstruction
por: Suzuki, Hidenori, et al.
Publicado: (2022)

Lymph node density in papillary thyroid carcinoma is a prognostic factor after adjusting for pathological stage
por: Suzuki, Hidenori, et al.
Publicado: (2018)

Impact of age for overall survival in head and neck sarcoma
por: Suzuki, Hidenori, et al.
Publicado: (2023)

Safety and Efficacy of Salvage Neck Dissection Following Carbon-ion Radiotherapy with Chemotherapy for a Patient with Mucosal Malignant Melanoma of Head and Neck
por: Suzuki, Hidenori, et al.
Publicado: (2020)

Lymph node ratio as a predictor for minor salivary gland cancer in head and neck
por: Suzuki, Hidenori, et al.
Publicado: (2021)

Serum CD109 levels reflect the node metastasis status in head and neck squamous cell carcinoma
por: Hagiwara, Sumitaka, et al.
Publicado: (2021)

Near-Infrared Photoimmunotherapy for Oropharyngeal Cancer
por: Nishikawa, Daisuke, et al.
Publicado: (2022)

Association between treatment package time and clinical predictors in oropharyngeal cancer
por: Suzuki, Hidenori, et al.
Publicado: (2020)

Total lesion glycolysis as a predictor of clinical T3–4a laryngeal cancer with laryngectomy or nonlaryngectomy
por: Suzuki, Hidenori, et al.
Publicado: (2021)

Pathological tumor volume predicts survival outcomes in oral squamous cell carcinoma
por: Mukoyama, Nobuaki, et al.
Publicado: (2018)

Total lesion glycolysis on FDG-PET/CT before salvage surgery predicts survival in laryngeal or pharyngeal cancer
por: Suzuki, Hidenori, et al.
Publicado: (2018)

Metabolic Tumour Volume as a Predictor of Survival for Sinonasal Tract Squamous Cell Carcinoma
por: Suzuki, Hidenori, et al.
Publicado: (2022)

The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor for head and neck cancer
por: Hanai, Nobuhiro, et al.
Publicado: (2018)

Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab
por: Minohara, Kiyoshi, et al.
Publicado: (2021)

Renal protective effect of a hydration supplemented with magnesium in patients receiving cisplatin for head and neck cancer
por: Kimura, Takahiro, et al.
Publicado: (2018)

Current topics and management of head and neck sarcomas
por: Kobayashi, Kenya, et al.
Publicado: (2023)

Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients
por: Matsuki, Takashi, et al.
Publicado: (2020)

Toxic epidermal necrolysis associated with nivolumab treatment for head and neck cancer
por: Koshizuka, Keiichi, et al.
Publicado: (2020)

Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study
por: Hanai, Nobuhiro, et al.
Publicado: (2020)

Frequent KRAS and HRAS mutations in squamous cell papillomas of the head and neck
por: Sasaki, Eiichi, et al.
Publicado: (2020)

Correction to: Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real‑world clinical practice: a multicentre retrospective clinical study
por: Hanai, Nobuhiro, et al.
Publicado: (2021)

Treatment and Outcomes of Carcinoma of the External and Middle Ear: The Validity of En Bloc Resection for Advanced Tumor
por: MATOBA, Takuma, et al.
Publicado: (2018)

The Heterogeneous Impact of Prediagnostic Folate Intake for Fluorouracil-Containing Induction Chemotherapy for Head and Neck Cancer
por: Sawabe, Michi, et al.
Publicado: (2023)

Effectiveness of nivolumab affected by prior cetuximab use and neck dissection in Japanese patients with recurrent or metastatic head and neck cancer: results from a retrospective observational study in a real-world setting
por: Kariya, Shin, et al.
Publicado: (2021)

New Prognostic and Predictive Markers in Head and Neck Tumors
por: Cantile, Monica, et al.
Publicado: (2016)

Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
por: Wakasaki, Takahiro, et al.
Publicado: (2020)

Real-World Outcomes and Prognostic Factors in Patients Receiving Nivolumab Therapy for Recurrent or Metastatic Head and Neck Carcinoma
por: Hori, Ryusuke, et al.
Publicado: (2019)

Outcomes of long-term nivolumab and subsequent chemotherapy in Japanese patients with head and neck cancer: 2-year follow-up from a multicenter real-world study
por: Yasumatsu, Ryuji, et al.
Publicado: (2021)

The Utility of Ultrasonography in the Diagnosis of Cervical Lymph Nodes after Chemoradiotherapy for Head and Neck Squamous Cell Carcinoma
por: Terada, Hoshino, et al.
Publicado: (2021)

Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab
por: Schwab, Katjana S., et al.
Publicado: (2018)

Unexpected Response to Nivolumab in a “Fast Progressor” Head and Neck Cancer Patient
por: Napolitano, Martina, et al.
Publicado: (2019)

Association of Pretreatment Neutrophil-to-Eosinophil Ratio with Clinical Outcomes in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab
por: Suzuki, Shinsuke, et al.
Publicado: (2022)

Prognostic impact of sarcopenia in patients with head and neck cancer treated with surgery or radiation: A meta-analysis
por: Takenaka, Yukinori, et al.
Publicado: (2021)

A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab
por: Kuba, Kiyomi, et al.
Publicado: (2022)

Tumor Infiltrating Lymphocytes are Prognostic Factors and Can Be Markers of Sensitivity to Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma
por: Suzuki, Hitomi, et al.
Publicado: (2022)

Role of Human Papilloma Virus and Lifestyle Factors in Overall Survival of Patients with Oropharyngeal Squamous Cell Carcinoma
por: Nishikawa, Daisuke, et al.
Publicado: (2022)

Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck
por: Hanna, Glenn J., et al.
Publicado: (2022)

LTBP2 is a prognostic marker in head and neck squamous cell carcinoma
por: Han, Liang, et al.
Publicado: (2016)

Human Leucocyte Antigens as Prognostic Markers in Head and Neck Squamous Cell Carcinoma
por: Dyckhoff, Gerhard, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rm6ghmnpqdv09e8shu61ern96d